Core Viewpoint - The announcement indicates that the company’s wholly-owned subsidiary, Shandong Danhong Pharmaceutical, has signed a clinical trial outsourcing contract with Beijing Zhuoyue Future for the registration of a new drug, which is expected to enhance the company's research and development capabilities and reduce costs [1] Group 1 - The contract involves a total of 480 cases (including a 20% dropout rate) with a total price of 60.338 million yuan (including tax) [1] - If the final sample size exceeds 520 cases, the additional cases will be charged at a rate of 108,890 yuan per case (including tax) [1] - Shandong Danhong's revenue for 2024 is projected to be 1.331 billion yuan, with a net profit of 226 million yuan; for the first nine months of 2025, revenue is reported at 1.402 billion yuan and net profit at 334 million yuan [1]

博雅生物公告，近日收到国家药品监督管理局签发的破伤风人免疫球蛋白《药品注册证书》(证书编 号：2025S03488)。破伤风人免疫球蛋白剂型为注射剂，规格为每瓶含破伤风抗体250IU（2.5ml）。公 司本次获得破伤风人免疫球蛋白《药品注册证书》，进一步丰富公司的产品管线，有助于提升公司的研 发积极性。 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its product "Cough Orange Granules," which is already in production and sales [1] Group 1: Product Information - "Cough Orange Granules" is a national secondary protected traditional Chinese medicine with functions for "clearing the lungs, stopping cough, and resolving phlegm" [1] - The product is indicated for cough with phlegm due to phlegm-heat obstructing the lungs, characterized by symptoms such as excessive phlegm, chest fullness, shortness of breath, dry throat, and itching [1] Group 2: Clinical Trial Approval - The company submitted an application to add a new indication for "acute exacerbation of chronic obstructive pulmonary disease (phlegm-heat obstructing the lungs)" and received approval for clinical trials [1] - This approval represents a milestone in the company's drug development efforts [1] Group 3: Financial Impact - The approval of the clinical trial does not have a significant impact on the company's short-term financial status or operating performance [1] - The sales of the product will not be affected by the receipt of the clinical trial approval notification [1]

Group 1: Pharmaceutical Business Performance - In the first half of 2025, the pharmaceutical segment achieved a revenue of CNY 4.751 billion, representing a year-on-year growth of 10.8% [2] - Sales revenue of Yunnan Baiyao aerosol exceeded CNY 1.453 billion, with a significant year-on-year increase of over 20.9% [2] - Other traditional Chinese medicine products showed remarkable growth, with sales of Canling Jianpi Granules exceeding CNY 100 million and Pudilan Anti-inflammatory Tablets nearing CNY 100 million [2] - Plant-based products, such as Qixue Kang Oral Liquid, reached sales of CNY 202 million, with a year-on-year growth of approximately 116.2% [2] Group 2: Nuclear Medicine R&D Progress - The INR101 diagnostic nuclear medicine project has initiated Phase III clinical trials, with 32 research centers established and 22 activated, enrolling 60 subjects [3] - The INR102 therapeutic nuclear medicine project has received a clinical trial notification, with Phase I trials underway and 12 patients enrolled for Phase II trials [3] Group 3: Health Products Business Performance - The health products segment reported a revenue of CNY 3.442 billion in the first half of 2025, reflecting a year-on-year growth of 9.46% [4] - The segment focuses on a full-channel operation strategy, enhancing offline distribution capabilities and increasing online channel investments [4] - The oral care category, particularly gum care toothpaste, maintains and gradually expands its leading advantage, while anti-sensitivity toothpaste shows breakthrough growth [4] Group 4: Online Sales Performance - The pharmaceutical segment's online sales increased by over 20% year-on-year, with a GMV of CNY 254 million generated from 4.845 million visitors [5] - Yunnan Baiyao toothpaste holds the top market share in the domestic all-channel market, while Yangyuanqing shampoo ranked first in Tmall's domestic anti-hair loss category during the 2025 "618" shopping festival [5] Group 5: Dividend Distribution - For the 2024 fiscal year, the company distributed a cash dividend of CNY 11.85 per 10 shares, totaling CNY 2.164 billion [6] - The total cash dividend for 2024, including special dividends, amounted to CNY 23.98 per 10 shares, representing 90.09% of the net profit attributable to shareholders [7] - In the first half of 2025, the company distributed a cash dividend of CNY 10.19 per 10 shares, totaling CNY 1.818 billion, with special dividends accounting for 50.05% of the net profit for the period [7]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 自願公告 產品開發的最新進展 石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 本集團已取得中國國家藥品監督管理局（「國家藥監局」）有關氨茶鹼片（100mg）的藥品生產 註冊批件，屬於化學藥品第3類，視同通過一致性評價，是國內企業第三家獲批。氨茶鹼片主要 用於支氣管哮喘、喘息型支氣管炎、阻塞性肺氣腫等緩解喘息症狀，也可用於治療心源性肺水 腫引起的哮喘。本集團的氨茶鹼原料藥已獲國家藥監局批准登記成為在上市製劑使用的原料藥。 董事局亦欣然公告，本集團已取得國家藥監局有關鹽酸丙卡特羅吸入溶液(0.5ml：50μg)及注射 用丁二磺酸腺苷蛋氨酸(0.5g)的藥品生產註冊批件，分別屬於化學藥品第3類及第4類，視同通 過一致性評價。鹽酸丙卡特羅吸入溶液主要用於緩解支氣管哮喘、慢性支氣管炎及肺氣腫以氣 流受限為基礎的各種症狀。注射用丁二磺酸腺苷蛋氨酸主要用於治療肝硬化前和肝 ...

Core Viewpoint - The company reported a revenue of 19.89 billion yuan for the first three quarters of 2025, representing a year-on-year decrease of 12.3%, but a growth of 3.4% year-on-year in Q3, with a net profit of 3.51 billion yuan, down 7.1% year-on-year, but a significant increase of 27% year-on-year in Q3 [1][2]. Group 1: Financial Performance - Revenue for Q3 2025 was 9.6 billion yuan, with an estimated internal profit of nearly 600 million yuan [1]. - The decline in revenue for the first three quarters was primarily due to the impact of the collection of authorized income in the drug business, which has now narrowed, and the gradual dissipation of the impact from the procurement of Duomeisu [1][2]. - The company expects continued improvement in revenue in Q4 2025, driven by the market expansion of new products such as Omaguzumab and Mingfule [1][2]. Group 2: Drug Business Outlook - The drug business revenue decreased by 17.2% year-on-year for the first three quarters of 2025, but the decline narrowed significantly compared to Q2 [2]. - The company anticipates a return to positive growth in the drug business by 2026, supported by the absence of major products in the 14th batch of centralized procurement and the market expansion of already launched products [2]. - New products such as TG103, HER2 bispecific antibodies, and Bai Zhi II are expected to be approved in 2026, contributing to revenue growth [2]. Group 3: Clinical Development - The company is actively advancing the clinical trials for EGFR ADC both domestically and internationally, with plans for Phase III trials in the near future [3]. - The focus of the clinical trials includes NSCLC classic mutations and wild-type cases, indicating a competitive ADC pipeline with strong data quality and enrollment [3]. Group 4: Business Development and Pipeline - The company confirmed a business development (BD) revenue of 1.54 billion yuan for the first three quarters of 2025, with four transactions completed [4]. - The company has a robust pipeline in oncology, metabolism, autoimmune diseases, and small nucleic acids, which is expected to support BD efforts in 2026 [4]. - Profit forecasts for 2025-2027 are adjusted to 4.552 billion yuan, 4.628 billion yuan, and 5.029 billion yuan respectively, with corresponding EPS estimates [4].

Core Viewpoint - Tian Tan Biological announced the withdrawal of the drug registration application for "Recombinant Human Coagulation Factor VIIa" by its subsidiary Chengdu Rongsheng Pharmaceutical Co., Ltd. due to the need for additional clinical trial data for pediatric patients under 12 years old [1] Group 1: Company Actions - The product's market authorization application was submitted to the National Medical Products Administration (NMPA) on January 2025 and received an acceptance notice [1] - Following the NMPA's review comments, Chengdu Rongsheng decided to withdraw the drug registration application to supplement the required clinical data [1] - The company plans to resubmit the drug registration application after completing the necessary clinical trials [1] Group 2: Impact on Business - The announcement states that the withdrawal of the drug registration application will not have a significant impact on the company's operating performance [1] - The company must complete the clinical trial data and pass the review and approval processes to achieve production and market sales [1] Group 3: Industry Considerations - The announcement highlights the long-term and uncertain nature of drug development, indicating potential risks for investors [1]

Core Viewpoint - The company reported a decline in revenue and profit for the first nine months of 2025, primarily due to industry policy impacts such as centralized procurement and price adjustments in the national medical insurance drug list [1][2]. Financial Performance - The company recorded revenue of RMB 19.891 billion and a profit attributable to shareholders of RMB 3.511 billion, representing a decrease of 12.3% and 7.1% respectively compared to the same period last year [1]. - The basic earnings per share attributable to shareholders was RMB 0.3072, down 4.1% year-on-year [1]. - The revenue from the pharmaceutical business was RMB 15.450 billion, including licensing fee income of RMB 1.540 billion, which decreased by 17.2% year-on-year [1]. - The raw material products business achieved sales revenue of RMB 3.006 billion, an increase of 10.3% compared to the previous year [1]. - The functional food and other businesses reported sales revenue of RMB 1.435 billion, up 11.2% year-on-year, mainly due to stable growth in sales of Guo Weikang [1]. Research and Development - R&D expenses increased by 7.9% to RMB 4.185 billion, accounting for 27.1% of the pharmaceutical business revenue [2]. - The company has nearly 90 products in various stages of clinical trials, with 14 submitted for market approval and over 30 key products in the registration clinical stage [2]. - The company is enhancing its internal innovation capabilities and increasing R&D investment, resulting in a rich pipeline of innovative assets [2]. - The company is actively promoting the internationalization of its R&D pipeline through licensing innovative products and strategic collaborations with multinational pharmaceutical companies [2].

Core Viewpoint - The company, GY Pharmaceutical (603707.SH), addresses investor concerns regarding its R&D capabilities, sales focus, and production base advantages, highlighting its strengths in these areas. Group 1: R&D Capabilities - The company currently employs over 500 R&D personnel, including renowned Chinese FDA quality experts, aseptic injection experts, and biological research and management experts, forming one of the best expert teams in China [1] - The company emphasizes its commitment to drug research and development, countering concerns about the lack of R&D background among its executives [1] Group 2: Sales Strategy - The company is a comprehensive pharmaceutical enterprise that integrates drug R&D, production, and sales, with a strong focus on pharmaceutical sales [1] - The company is actively expanding its overseas sales market, indicating a strategic move to enhance its market presence beyond domestic sales [1] Group 3: Production Base and Advantages - The company's production bases are primarily located in Nanjing and Chengdu, with a total of 12 production lines approved by the US FDA (9 in Nanjing and 3 in Chengdu) [1] - The production facilities utilize reliable, advanced, and highly automated equipment, which provides significant advantages in production efficiency, stability, and resource consumption while ensuring high-quality production [1]

Group 1 - The company, Kew Flower Pharmaceutical (002737.SZ), announced a plan to invest up to 50 million yuan for the development of traditional Chinese medicine with the same name and formula, generic drug projects aligned with consistency evaluation, and research to expand indications for existing products [1] - The management has been authorized to oversee the progress and specific matters related to the project development [1] - This initiative aims to enrich the product pipeline and strengthen the company's long-term development momentum [1]